Background
Generic drug name | Target | Approved population | Type | EMA approved treatment regimens in NSCLC | FDA approved treatment regimens in NSCLC |
---|---|---|---|---|---|
Afatinib | EGFR | EGFR positive NSCLC patients | Tyrosine-kinase inhibitor |
Under review
|
Under review
|
Bevacizumab | VEGF | All NSCLC patients | Recombinant humanized monoclonal antibody | In addition to platinum-based chemotherapy for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent NSCLC other than predominantly squamous cell histology (Aug 2007) | Non-squamous NSCLC, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced recurrent or metastatic disease (Oct 2006) |
Cetuximab | EGFR | Chimeric monoclonal IgG1 antibody |
None; Merck KGaA withdrew its application formally in Sep 2012
| - | |
Crizotinib | ALK | ALK positive NSCLC patients | Anaplastic lymphona kinase inhibitor | Adult patients with previously treated ALK-positive NSCLC (Oct 2012) | Patients with locally advanced or metastatic NSCLC that is ALK-positive as detected by an FDA-approved test (Aug 2011) |
Erlotinib | EGRF | EGFR positive NSCLC patients | Tyrosine-kinase inhibitor | Patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen (Oct 2005) | • Treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen (Nov 2004) |
• Maintenance treatment of patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy (April 2010) | |||||
• First-line treatment of metastatic NSCLC patients whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (May 2013) | |||||
Monotherapy for the continued treatment of patients with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited (May 2003). The approval was limited to cancer patients who, in the opinion of their treating physician, are currently benefiting, or have previously benefited, from gefitinib treatment (Jun 2005) | |||||
Gefitinib | EGFR | EGFR positive NSCLC patients | Tyrosine-kinase inhibitor | Adult patients with locally advanced or metastatic NSCLC with activating mutations of EGFR (Jun 2009) |
Method
Review objective
| The objective of this article is to review the economic evidence of treatment of NSCLC with targeted agents. |
Participants
| Studies of participants diagnosed with NSCLC. Studies were not restricted based on age of the participants or treatment lines. |
Interventions/Comparison
| Studies about treatments with approved targeted agents or agents still going through the approval process. The review is not limited to specific comparators |
Outcomes
| ICER, e.g. cost per QALY or cost per life year gained/saved |
Questions | Points | Yes | No | |
---|---|---|---|---|
1. | Was the study objective presented in a clear, specific, and measurable manner? |
7
| ||
2. | Were the perspective of the analysis (societal, third-party payer, etc.) and reasons for its selection stated? |
4
| ||
3. | Were variable estimates used in the analysis from the best available source (i.e., randomized control trial - best, expert opinion - worst)? |
8
| ||
4. | If estimates came from a subgroup analysis, were the groups prespecified at the beginning of the study? |
1
| ||
5. | Was uncertainty handled by (1) statistical analysis to address random events, (2) sensitivity analysis to cover a range of assumptions? |
9
| ||
6. | Was incremental analysis performed between alternatives for resources and costs? |
6
| ||
7. | Was the methodology for data abstraction (including the value of health states and other benefits) stated? |
5
| ||
8. | Did the analytic horizon allow time for all relevant and important outcomes? Were benefits and costs that went beyond 1 year discounted (3% to 5%) and justification given for the discount rate? |
7
| ||
9. | Was the measurement of costs appropriate and the methodology for the estimation of quantities and unit costs clearly described? |
8
| ||
10. | Were the primary outcome measure(s) for the economic evaluation clearly stated and did they include the major short-term, long-term, and negative outcomes? |
6
| ||
11. | Were the health outcomes measures/scales valid and reliable? If previously tested valid and reliable measures were not available, was justification given for the measures/scales used? |
7
| ||
12. | Were the economic model (including structure), study methods and analysis, and the components of the numerator and denominator displayed in a clear, transparent manner? |
8
| ||
13. | Were the choice of economic model, main assumptions, and limitations of the study stated and justified? |
7
| ||
14. | Did the author(s) explicitly discuss direction and magnitude of potential biases? |
6
| ||
15. | Were the conclusions/recommendations of the study justified and based on the study results? |
8
| ||
16. | Was there a statement disclosing the source of funding for the study? |
3
| ||
Total Points |
100
|
Results
Author (Publication year) | Country/perspective (Pharma sponsored?) | Treatment line | Treatment | Incremental costs | LYG gained | QALY’s gained | ICER (per LYG) | ICER (per QALY) |
---|---|---|---|---|---|---|---|---|
In US-$ | In US-$ | In US-$ | ||||||
Erlotinib vs. BSC/chemotherapy
| ||||||||
Wang et al. (2013) [16] | China/health care system (no) | First | Erlotinib vs. carboplatin-gemcitabine chemotherapy | $ 48,119*** | 0.84 | 0.58 | $ 30,455 | $ 85,927 |
Vergnenegre et al. (2012) [13] | France/payer (yes) | First maintenance | Erlotinib plus BSC vs. BSC | 11,140 € ($ 15,476*) | 0.28 | 39,783 € ($ 55,266*) | ||
Germany/payer (yes) | 13,141 € ($ 18,255*) | 0.28 | 46,931 € ($ 65,196*) | |||||
Italy/payer (yes) | 7,808 € ($ 10,847*) | 0.28 | 27,885 € ($ 38,738*) | |||||
Walleser et al. (2012) [14] | UK/payer (no) | First maintenance | Erlotinib vs. BSC | 7,898 € ($ 10,460*) | 0.39 | 20,711 € ($ 27,430*) | ||
Germany/payer (no) | 9,580 € ($ 12,688*) | 25,124 € ($ 33,275*) | ||||||
France/payer (no) | 8,873 € ($ 11,752*) | 23,271 € ($ 30,821*) | ||||||
Spain/payer (no) | 8,488 € ($ 11,242*) | 22,261 € ($ 29,483*) | ||||||
Italy/payer (no) | 8,149 € ($ 10,793*) | 21,368 € ($ 28,300*) | ||||||
Klein et al. (2010) [15] | USA/payer (yes) | First maintenance | Erlotinib vs. pemetrexed | $ -24,474 | -0.1629 | no statement | ||
Erlotinib vs. BSC | $ 7,470 | 0.0982 | $ 76,069** | |||||
Araújo et al. (2008) [17] | Portugal/health care system (yes) | Subsequent | Erlotinib vs. BSC | 10,366 € ($ 15,184) | 0.15 | 0.064 | 70,424 € ($ 103,159) | 161,742 € ($ 236,924) |
Erlotinib vs. docetaxel | -2,784 € ($ -4,078) | 0 | 0.025 | Dominant | Dominant | |||
Erlotinib vs. pemetrexed | -6,284 € ($ -9,205) | 0 | 0.009 | Dominant | Dominant | |||
Carlson et al. (2008) [12] | USA/payer (yes) | Subsequent | Erlotinib vs. docetaxel | $ -2,127 | 0.01 | Dominant | ||
Erlotinib vs. pemetrexed | $ -6,782 | 0.01 | Dominant | |||||
Lewis et al. (2010) [18] | UK/NHS (yes) | Subsequent (second) | Erlotinib vs. docetaxel | £ -226 ($ -352) | 0.032 | Dominant | ||
Thongprasert et al. (2012) [19] | Thailand/payer (yes) | Subsequent | Erlotinib vs. docetaxel | $ 1,746 | 0.0140 | $ 124,703 | ||
Cromwell et al. (2011) [20] | Canada/health care system (no) | Subsequent | Erlotinib vs. docetaxel | 2,891 CAD ($ 2,529) | 0.003 | Not calculated, no statistical differences | ||
Cromwell et al. (2012) [21] | Canada/health care system (no) | Subsequent | Erlotinib vs. BSC | 11,102 CAD ($ 9,712) | 0.25 | 36,838 CAD ($ 32,226) | ||
Bradbury et al. (2010) [22] | Canada/health care system (no) | Subsequent | Erlotinib vs. BSC | 12,303 CAD ($ 11,454) | 0.13 | 94,638 CAD ($ 88,109) | ||
Gefitinib vs. chemotherapy
| ||||||||
Zhu et al. (2013) [23] | China/health care system (no) | First | Gefitinib (WT patients only) vs. routine care | $ 26,150 | 0.74 | 0.46 | $ 35,337 | $ 57,066 |
Thongprasert et al. (2012) [19] | Thailand/payer (yes) | Subsequent | Gefitinib vs. docetaxel | $ -247 | / | 0.0140 | / | Dominant |
Erlotinib (various combinations)
| ||||||||
Chouaid et al. (2012) [24] | France/payer (yes) | First | Erlotinib followed by docetaxel and gemcitabine (DG) vs. DG followed by erlotinib (fit elderly patients) | 3,954 € ($ 5,497) | / | -0.01 | / | 395,400 € ($ 549,700) |
Chouaid et al. (2013) [25] | France/payer (yes) | First | Erlotinib followed by gemcitabine vs. gemcitabine followed by erlotinib (frail elderly patients) | 130€ ($ 181) | / | -0.02 | / | / |
Carlson et al. (2009) [26] | USA/societal (no) | Subsequent | EGFR protein expression test (erlotinib if high expression/docetaxel if low expression) vs. No testing (erlotinib monotherapy) | $ 6,274 | / | 0.04 | / | $ 179,612 |
EGFR gene copy number test (erlotinib if high number/docetaxel if low number) vs. No testing (erlotinib monotherapy) | $ 9,209 | 0.12 | 0.06 | $ 78,367 | $ 162,018 | |||
Bevacizumab (plus chemotherapy) vs. chemotherapy
| ||||||||
Giuliani et al. (2010) [27] | Italy/payer (yes) | First | Bevacizumab plus cisplatin and gemcitabine vs. pemetrexed plus cisplatin | 4,007 € ($ 5,566) | 0.12 | 34,919 € ($ 48,509) | ||
Ahn et al. (2011) [28] | Korea/payer (yes) | First | Bevacizumab plus cisplatin and gemcitabine vs. cisplatin plus pemetrexed | $ 33,322 | 1.10 | $ 30,318 | ||
Taiwan/payer (yes) | First | Bevacizumab plus cisplatin and gemcitabine vs. cisplatin plus pemetrexed | $ 64,541 | 1.19 | $ 54,317 | |||
Goulart et al. (2011) [29] | USA/payer (no) | First | Bevacizumab plus carboplatin-paclitaxel vs. carboplatin-paclitaxel | $ 71,620 | 0.23 | 0.13 | $ 308,982 | $ 559,610 |
Klein et al. (2009) [30] | USA/payer (yes) | First | Carboplatin/paclitaxel/bevacizumab vs. cisplatin/pemetrexed | $ 24,528 | 0.0727 | 0.0244 | $ 337,179 | $ 1,006,065 |
Klein et al. (2010) [15] | USA/payer (yes) | First | Bevacizumab vs. pemetrexed | $ 9,187 | -0.0480 | Dominated |
Erlotinib vs. BSC or chemotherapy
Gefitinib vs. chemotherapy
Erlotinib (various combinations)
Bevacizumab (plus chemotherapy) vs. chemotherapy
Quality assessment (QHES)
Study | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Score |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wang et al. (2013) [16] | √ | √ | x | √ | √ | √ | √ | √ | √ | x | x | √ | √ | x | x | √ | 65 |
Vergnenegre et al. (2012) [13] | √ | √ | x | √ | x | √ | x | √ | x | x | √ | √ | x | x | √ | √ | 51 |
Walleser et al. (2012) [14] | √ | √ | x | √ | √ | √ | √ | √ | x | √ | x | √ | x | x | √ | x | 61 |
Klein et al. (2010) [15] | √ | √ | x | x | x | x | x | √ | x | √ | √ | √ | √ | x | √ | √ | 57 |
Araújo et al. (2008) [17] | √ | √ | x | √ | √ | √ | √ | √ | x | √ | √ | x | √ | x | x | √ | 62 |
Carlson et al. (2008) [12] | √ | √ | x | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 92 |
Lewis et al. (2010) [18] | √ | √ | x | √ | x | √ | √ | √ | x | √ | √ | x | √ | x | √ | √ | 61 |
Thongprasert et al. (2012) [19] | √ | √ | x | √ | x | √ | x | √ | x | √ | √ | √ | √ | x | √ | x | 61 |
Cromwell et al. (2011) [20]* | √ | √ | √ | √ | x | √ | √ | √ | √ | √ | √ | n.a. | n.a. | √ | √ | √ | 76 |
Cromwell et al. (2012) [21]* | √ | √ | √ | √ | x | √ | √ | √ | √ | √ | √ | n.a. | n.a. | √ | √ | √ | 76 |
Bradbury et al. (2010) [22]* | √ | √ | √ | √ | √ | √ | √ | √ | √ | x | √ | n.a. | n.a. | √ | √ | √ | 79 |
Zhu et al. (2013) [23] | √ | √ | x | √ | √ | √ | x | √ | √ | √ | √ | √ | x | √ | √ | √ | 80 |
Chouaid et al. (2012) [24] | √ | √ | x | √ | x | √ | x | x | x | x | √ | x | √ | x | √ | √ | 43 |
Chouaid et al. (2013) [25] | √ | √ | x | √ | x | √ | x | x | √ | x | √ | x | x | x | √ | √ | 44 |
Carlson et al. (2009) [26] | √ | √ | x | √ | √ | √ | √ | √ | x | x | √ | √ | √ | √ | √ | √ | 78 |
Giuliani et al. (2010) [27] | √ | √ | x | √ | x | √ | x | √ | x | √ | √ | √ | √ | x | √ | √ | 64 |
Ahn et al. (2011) [28] | √ | √ | x | √ | √ | √ | √ | √ | x | √ | √ | √ | √ | x | √ | √ | 78 |
Goulart et al. (2011) [29] | √ | √ | x | √ | √ | √ | √ | √ | √ | x | √ | √ | √ | √ | √ | √ | 86 |
Klein et al. (2009) [30] | √ | √ | x | √ | x | x | x | x | x | √ | √ | √ | √ | √ | √ | √ | 57 |
Statement frequency
| 19 | 19 | 3 | 18 | 9 | 17 | 11 | 16 | 8 | 12 | 17 | 12 | 12 | 8 | 17 | 17 |